The safe and appropriate use of all Bayer medicines is our highest priority. Prescribe Xarelto with care.
This section contains practical guidance and tools to help you identify patients at increased risk of haemorrhagic events, and manage them appropriately.
Responsible Use of Xarelto®
Bleeding is a safety concern with all anticoagulants
All licenced anticoagulants deliver a positive benefit risk profile. However, all anticoagulants can increase the risk of bleeding.1
Some patients are at greater risk of bleeding
For which patients should Xarelto be prescribed with care, or not at all?
Please refer to the Summary of Product Characteristics for full safety information and precautions for use.
Xarelto is not recommended in patients with an increased bleeding risk such as:2
- congenital or acquired bleeding disorders
- uncontrolled severe arterial hypertension
- other gastrointestinal disease without active ulceration that can potentially lead to bleeding complications (e.g. inflammatory bowel disease, oesophagitis, gastritis and gastroesophageal reflux disease)
- vascular retinopathy
- bronchiectasis or history of pulmonary bleeding
Further information about patient selection criteria and dosing are provided in the Prescriber Aid
The importance of patient education and compliance
A major component of responsible use of anticoagulant therapy rests with the patient. To benefit from Xarelto therapy, patients must take their treatment exactly as prescribed.
It is imperative that your patients understand as best as they can the importance of continued anticoagulation.
Patients also need to be able to recognise the signs and symptoms of bleeding and know when they should seek medical attention.
Patient information resources and educational video clips may help you convey this important information to your patients.
By following this careful path to safe and appropriate Xarelto prescribing, you will help to ensure your patients obtain the greatest therapeutic benefit from treatment, without exposing them to unnecessary risk.
PP-XAR-ALL-1803-1
References
- Ruff CT, et al. Lancet. 2014;383:955-962. Return to content
- Xarelto (rivaroxaban). Summary of Product Characteristics. Xarelto (rivaroxaban). Summary of Product Characteristics. Return to content